Abstract
Current Neuropharmacology
Title: Subject Index to Volume 2
Volume: 3 Issue: 1
Author(s): Bentham Science Publishers
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Bentham Science Publishers , Subject Index to Volume 2, Current Neuropharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570159052773378
DOI https://dx.doi.org/10.2174/1570159052773378 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
10
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Intersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Current Pharmaceutical Biotechnology Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Graphene Oxide-Based Nanocarriers for Cancer Imaging and Drug Delivery
Current Pharmaceutical Design Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Functional Cross-Talk between Adenosine and Metabotropic Glutamate Receptors
Current Neuropharmacology Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Considering Autotaxin Inhibitors in Terms of 2D-QSAR and 3D-Mapping- Review and Evaluation
Current Medicinal Chemistry 5-HT3 Receptors
Current Pharmaceutical Design Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology